Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. H-CYTE, Inc.
  6. News
  7. Summary
    HCYT   US4041241096

H-CYTE, INC.

(HCYT)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

H-CYTE, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

04/07/2021 | 05:23pm EDT

Item 1.01 Entry into a Material Definitive Agreement

On April 1, 2021, H-Cyte, Inc. (the "Company") entered into a Secured Convertible Note Purchase Agreement (the "Note Purchase Agreement") with five (5) investors (the "Holders"). Pursuant to the terms of the Note Purchase Agreement, the Company sold promissory notes in the aggregate principal amount of $2,575,000. The Notes are due and payable on March 31, 2022 and bear interest at an annual rate of 8%. The Notes are convertible into shares of Common Stock at a discount of 20% to the price paid for such New Securities in the next financing that meets the definition of a Qualified Financing as defined in the Note Purchase Agreement. The Notes are secured by all of the assets of the Company under a security agreement with the Holders. The lead investor of the Note Purchase Agreement, FWHC Bridge, LLC, advanced $1,500,000 of the total amount to the Company. FWHC is an affiliated entity of FWHC, LLC. which is a principal stockholder of the Company. An additional affiliate of FWHC LLC advanced an additional $25,000.

The foregoing description of the terms of the Note Purchase Agreement and the Note are not complete and are qualified in their entirety by the full text of the Note Purchase Agreement and the Note which are filed as Exhibit 10.1 and 4.1, respectively.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The information set forth in Item 1.01 is incorporated by reference herein.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On April 1, 2021, the Board of Directors of the Company approved and granted an aggregate of 49,750,000 stock options to certain directors and officers of the Company having an exercise price of $0.07 per share and an expiration date of ten years from the date of grant (The "Options). The Director's Options vest over a period of three years, and the Chief Executive Officer and Chief Financial Officer's Options vest over a period of four years.

Item 9.01 Financial Statements and Exhibits



(d) Exhibits.



Exhibit Number   Description

4.1                Secured Convertible Promissory Note dated April 1, 2021
10.1               Secured Convertible Note Purchase Agreement dated April 1,
                 2021

© Edgar Online, source Glimpses

All news about H-CYTE, INC.
04/08H-CYTE, INC.  : Entry into a Material Definitive Agreement, Financial Statements..
AQ
04/07H-CYTE, INC.  : Entry into a Material Definitive Agreement, Creation of a Direct..
AQ
03/25H CYTE  : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
01/19H-CYTE, INC.  : Change in Directors or Principal Officers (form 8-K)
AQ
2020H CYTE  : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2020H-CYTE, INC.  : Entry into a Material Definitive Agreement, Change in Directors ..
AQ
2020H CYTE  : Robert Greif named Chief Executive Officer of H-CYTE
AQ
2020Robert Greif named Chief Executive Officer of H-CYTE
GL
2020H-CYTE, INC.  : Unregistered Sale of Equity Securities, Other Events (form 8-K)
AQ
2020H-CYTE EXTENDS RIGHTS OFFERING TO 5 : 00 PM Eastern Time on Friday, September 11..
GL
More news
Financials (USD)
Sales 2020 2,15 M - -
Net income 2020 -6,46 M - -
Net cash 2020 0,47 M - -
P/E ratio 2020 -0,27x
Yield 2020 -
Capitalization 4,63 M 4,63 M -
EV / Sales 2019 1,72x
EV / Sales 2020 0,75x
Nbr of Employees -
Free-Float 20,1%
Chart H-CYTE, INC.
Duration : Period :
H-CYTE, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Robert Greif President & Chief Executive Officer
Jeremy Daniel Chief Financial & Accounting Officer
Raymond Monteleone Chairman
Tanya Rhodes Chief Technology Officer
William E. Horne Director
Sector and Competitors
1st jan.Capitalization (M$)
H-CYTE, INC.108.72%5
ABBOTT LABORATORIES8.64%211 335
MEDTRONIC PLC8.16%171 070
BECTON, DICKINSON AND COMPANY-1.43%71 725
HOYA CORPORATION-7.88%44 625
ALIGN TECHNOLOGY, INC.3.77%43 881